Exelixis Signs an Exclusive Option and License Agreement with Iconic Therapeutics for Advancing ADC Program

Shots:

• Iconic to receive $7.5M upfront, funds for preclinical development and is eligible for option exercise payment, development, regulatory & commercial milestones, royalties on sales. Exelixis to get an option to license Iconic’s ICON-2 ADC program and will exercise its option at IND filing
• The focus of the collaboration is to robust Exelixis’s oncology portfolio by developing therapies utilizing Iconic’s Tissue Factor antibody expertise
• ICON-2 is a second-generation ADC targeting Tissue Factor in solid tumors as TF overexpression accelerates angiogenesis, metastasis leading to tumor development and progression

Click here to read full press release/ article | Ref: Exelixis | Image: Iconic Therapeutics